# US 2020/0390693 A1 · Liquid composition comprising vegf antagonist

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390693 A1
- Document ID: US20200390693A1
- Status: Published application
- Kind: A1
- Application number: 16/770,858
- Filed: 2018-12-18
- Published: 2020-12-17
- Earliest claimed: 2017-12-22
- Assignees: Samsung Bioepis Co., Ltd.
- Applicants: Samsung Bioepis Co., Ltd.
- Inventors: Inae KIM; Youngseok JUNG; Yong Min JANG; Wonjung YOO; Jaemin LEE; Yongkook KIM
- Web page: https://patentgrep.com/patent/US20200390693A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 38/179: {for growth factors; for growth regulators}
- A61K 47/02: Inorganic compounds
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- C07K 14/49: Platelet-derived growth factor [PDGF]
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/32: fusions with soluble part of a cell surface receptor, "decoy receptors"
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided are: a composition for stabilizing a protein, the composition containing a buffer that includes phosphate, histidine, or a combination thereof, and a stabilizer that does not include sodium chloride and/or includes one or more selected form the group consisting of trehalose, sucrose and mannitol; a stabilized liquid composition of protein, containing the composition for stabilization and a protein; and a method for preparing a stabilized liquid composition by using the composition for stabilization.

## Claims

### Claim at position 1

1-28. (canceled)

### Claim 29

A liquid composition comprising:
(1) a VEGF antagonist of 5 mg/ml to 100 mg/ml;
(2) a buffer of 1 to 50 mM, comprising phosphoric acid or a pharmaceutically acceptable salt of the acid and having pH ranging from 4 to 8; and
(3) a stabilizer of 7.8 to 10% (w/v),
wherein the liquid composition does not comprise sodium chloride.

### Claim 30 (depends on 29)

The liquid composition according to claim 29, wherein the amount of the VEGF antagonist is 20 mg/ml to 60 mg/ml.

### Claim 31 (depends on 29)

The liquid composition according to claim 29, wherein the pH of the liquid composition is 5.8 to 6.2.

### Claim 32 (depends on 29)

The liquid composition according to claim 29, wherein the concentration of the buffer in the composition is 1 to 20 mM.

### Claim 33 (depends on 29)

The liquid composition according to claim 29, wherein the buffer is sodium phosphate.

### Claim 34 (depends on 29)

The liquid composition according to claim 29, wherein the amount of the stabilizer is 7.8 to 8.2% (w/v).

### Claim 35 (depends on 29)

The liquid composition according to claim 29, wherein the stabilizer is at least one selected from the group consisting of trehalose, sucrose, and a combination thereof.

### Claim 36 (depends on 29)

The liquid composition according to claim 29, further comprising a surfactant.

### Claim 37 (depends on 36)

The liquid composition according to claim 36, wherein the surfactant is comprised in an amount of 0.001 to 3% (w/v), based on the total composition.

### Claim 38 (depends on 36)

The liquid composition according to claim 36, wherein the surfactant is at least one selected from the group consisting of polysorbate 20, polysorbate 80, and a combination thereof.

### Claim 39 (depends on 29)

The liquid composition according to claim 29, which is aqueous and isotonic.

### Claim 40 (depends on 29)

The liquid composition according to claim 29, wherein the composition is aqueous and has osmotic pressure of 200 to 400 mOsm/kg.

### Claim 41 (depends on 29)

The liquid composition according to claim 29, wherein the VEGF antagonist is aflibercept.

### Claim 42 (depends on 29)

A parenteral formulation for intravitreal administration, comprising the liquid composition according to claim 29.

### Claim 43

A liquid composition comprising,
(1) aflibercept of 30 mg/ml to 50 mg/ml;
(2) a buffer of 1 to 20 mM, comprising sodium phosphate and having pH ranging from 5.2 to 7.2;
(3) a stabilizer of 7.8 to 10% (w/v); and
(4) a surfactant of 0.01 to 0.1% (w/v),
wherein the liquid composition does not comprise sodium chloride.

### Claim 44 (depends on 43)

The liquid composition according to claim 43, wherein the pH of the liquid composition is 5.8 to 6.2.

### Claim 45 (depends on 43)

The liquid composition according to claim 43, wherein the amount of the stabilizer is 7.8 to 8.2% (w/v).

### Claim 46 (depends on 43)

The liquid composition according to claim 43, wherein the stabilizer is at least one selected from the group consisting of trehalose, sucrose, and a combination thereof.

### Claim 47 (depends on 43)

The liquid composition according to claim 43, wherein the surfactant is at least one selected from the group consisting of polysorbate 20, polysorbate 80, and a combination thereof.

### Claim 48 (depends on 43)

A parenteral formulation for intravitreal administration, comprising the liquid composition according to claim 43.

### Claim 49

A liquid composition comprising,
(1) aflibercept of 30 mg/ml to 50 mg/ml;
(2) a buffer of 1 to 20 mM, comprising sodium phosphate;
(3) a sucrose of 7.8 to 10% (w/v); and
(4) a polysorbate 20 of 0.01 to 0.1% (w/v);
wherein the liquid composition has pH of 6.2 and does not comprise sodium chloride.
